Sage Therapeutics, Inc.

États‑Unis d’Amérique


Commandez votre montre hebdomadaire Sage Therapeutics, Inc.
Quantité totale PI 375
Rang # Quantité totale PI 3 500
Note d'activité PI 3,2/5.0    292
Rang # Activité PI 2 438
Symbole boursier
ISIN US78667J1088
Capitalisation 343M  (USD)
Industrie Biotechnology
Secteur Healthcare
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

170 26
56 9
96 4
14
 
Dernier brevet 2025 - 19-nor c3,3-disubstituted c21-n-...
Premier brevet 2012 - Neuroactive steroids, compositio...
Dernière marque 2025 - Sage Therapeutics
Première marque 2014 - SAGE THERAPEUTICS

Industrie (Classification de Nice)

Derniers inventions, produits et services

2025 Invention Crystalline 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid. This invention relates to a cryst...
Invention Nmda receptor positive allosteric modulatory compositions and methods of use thereof. Disclosed h...
Invention Nmda receptor-modulating compounds and methods of use thereof. Compounds are provided according t...
P/S Pharmaceutical preparations.
Invention Neuroactive steroids and compositions thereof. Provided herein is a compound of Formula (I): P...
P/S Providing health information; Providing a web site featuring medical information
Invention Oxysterols and methods of use thereof. Compounds are provided according to Formula (III): Comp...
Invention Neuroactive steroids and their methods of use. Provided herein is a compound of Formula (I) or a...
2024 P/S Providing health information; patient support services relating to the treatment of postpartum de...
Invention 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof. Provided herein ar...
Invention 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof. Provided herein ...
Invention Compositions and methods for treating cns disorders. Described herein are neuroactive steroids o...
Invention Oxysterols and methods of use thereof. Compounds are provided according to Formula (A); and phar...
Invention 9(11)-unsaturated neuroactive steroids and their methods of use. Provided herein is a compound o...
Invention Oxysterols and methods of use thereof. Compounds are provided according to Formula (I) and pharm...
Invention Neuroactive steroids, compositions, and uses thereof. Compounds are provided according to Formul...
Invention Crystalline forms of a neuroactive steroid. This invention relates to crystalline forms of anhyd...
Invention Method of treating cns disorders with neurosteroids and gabaergic compounds. Provided herein are...
Invention Neuroactive steroids, compositions, and uses thereof. Described herein are methods of treating t...
Invention Neuroactive steroid formulations and methods of treating cns disorders. Formulations of comprisi...
Invention Compositions and methods for treating cns disorders. Provided herein is a compound of Formula (I...
P/S Pharmaceutical preparations
P/S Pharmaceutical preparations
Invention Methods of treating epilepsy or status epilepticus. Described herein are methods of treating epi...
Invention Neuroactive steroid formulations and methods of use thereof. Described herein are pharmaceutical ...
Invention Lymphatic system-targeting compounds. The disclosure provides lymphatic system-targeting compound...
P/S Pharmaceutical preparations. Providing health and medical information about diseases, disorders a...
Invention C7, c12, and c16 substituted neuroactive steroids and their methods of use. Described herein are...
Invention Neuroactive steroids and their methods of use. 55c is carbon-bound substituted or unsubstituted h...
Invention Oxysterols and methods of use thereof. 8, and n are as defined herein. Compounds of the present i...
Invention C7 substituted oxysterols and methods of use thereof. Compounds are provided according to Formula...
P/S Pharmaceutical preparations for use in the treatment of central nervous system diseases and disor...
Invention Neuroactive steroids and methods of use thereof. 3beta, 17beta disubstituted steroidal compounds...
2023 Invention Oxysterols and methods of use thereof. 5 are as defined herein. Compounds of the present inventio...
Invention Method of screening compounds for treating cns disorders. Provided herein are screening methods ...
P/S House mark for pharmaceutical preparations Providing health and medical information about disease...
Invention Compounds for treating cns disorders. Provided herein in part is a compound of Formula (I): or a...
P/S Pharmaceutical preparations for the treatment of central nervous system diseases and disorders, d...
Invention Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of c...
Invention Neuroactive steroids for treatment of cns-related disorders. The present disclosure relates to m...
Invention Neuroactive steroids for treatment of gastrointestinal diseases or conditions. The present discl...
2022 Invention Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators. ...
Invention Neuroactive steroid for the treatment of huntington's disease. Provided herein are methods for i...
Invention Deuterated positive nmda-modulating compounds and methods of use thereof. Deuterated compounds a...
Invention Positive nmda-modulating compounds and methods of use thereof. Compounds are provided according ...
P/S pharmaceutical preparations for the treatment of epilepsy, essential tremors, Parkinson's disease...
Invention Neuroactive steroid for the treatment of alzheimer's disease. The present disclosure relates to ...
2020 P/S House mark for pharmaceutical preparations
P/S Pharmaceutical products.
2019 P/S Pharmaceutical preparations for the treatment of epilepsy, depression, Parkinson's disease, essen...
P/S house mark for pharmaceutical preparations
P/S Providing health and medical information about postpartum depression and treatment; patient suppo...
2018 P/S Pharmaceutical preparations for the treatment of central nervous system diseases and disorders; p...
P/S Providing information in the fields of health, medicine, and pharmaceuticals related to depression
P/S Pharmaceutical preparations for the diagnosis and treatment of central nervous system disorders, ...
2017 P/S pharmaceutical preparations
P/S pharmaceutical preparations for the treatment of postpartum depression
P/S Prescription pharmaceutical preparations for the treatment of epilepsy, depression and postpartum...
P/S Pharmaceutical preparations. Pharmaceutical research and development services.